European Case Law Identifier: | ECLI:EP:BA:2016:T045415.20160725 | ||||||||
---|---|---|---|---|---|---|---|---|---|
Date of decision: | 25 July 2016 | ||||||||
Case number: | T 0454/15 | ||||||||
Application number: | 06027055.0 | ||||||||
IPC class: | A61K 38/29 A61P 19/08 A61K 33/06 A61K 31/59 |
||||||||
Language of proceedings: | EN | ||||||||
Distribution: | D | ||||||||
Download and more information: |
|
||||||||
Title of application: | hPTH(1-34) for use in preventing or reducing the incidence or severity of vertebral and / or non vertebral fracture in a male human | ||||||||
Applicant name: | Eli Lilly and Company | ||||||||
Opponent name: | Zentiva k.s. STADA Arzneimittel AG Teva Pharmaceutical Industries Ltd. |
||||||||
Board: | 3.3.04 | ||||||||
Headnote: | - | ||||||||
Relevant legal provisions: |
|
||||||||
Keywords: | Withdrawal of approval of text on which patent was granted - appeal dismissed | ||||||||
Catchwords: |
- |
||||||||
Cited decisions: |
|
||||||||
Citing decisions: |
|
Source: http://www.epo.org/law-practice/case-law-appeals/recent/t150454eu1.html
Date retrieved: 17 May 2021